Fig. 1 | Scientific Reports

Fig. 1

From: Discovery of novel serum peptide biomarkers for cholangiocarcinoma recurrence through MALDI-TOF MS and LC–MS/MS peptidome analysis

Fig. 1

Peptide mass fingerprint of serum peptides using MALI-TOF MS analysis from CCA patients. (A) The average spectra of serum samples from early recurrent CCA (upper panel) and late redcurrant CCA (lower panel) in the range of 1000–6,000 m/z. The dashed lines highlight the positions of peptide m/z values that demonstrate distinct differences. (B) Orthogonal Partial Least Squares Discriminant Analysis (OPLS-DA). (C) Cross-validation of the OPLS-DA model assessed classification performance using accuracy, R2Y (goodness of fit), and Q2Y (predictive ability). (E) A permutation test with 1,000 permutations was performed on the OPLS-DA model, yielding an empirical p < 0.001.

Back to article page